参考文献/References:
[1] Tocchetti CG,Cadeddu C,di Lisi D,et al. From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity:a translational overview[J]. Antioxid Redox Signal,2019,30(18):2110-2153.
[2] Suter TM,Ewer MS. Cancer drugs and the heart:importance and management[J]. Eur Heart J,2013,34(15):1102-1111.
[3] Darby SC,Ewertz M,Mc Gale P,et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]. N Engl J Med,2013,368(11):987-998.
[4] Smith LA,Cornelius VR,Plummer CJ,et al. Cardiotoxicity of anthracycline agents for the treatment of cancer:systematic review and meta-analysis of randomised controlled trials[J]. BMC Cancer,2010,10:337.
[5] Ajith TA,Jayakumar TG. Mitochondria-targeted agents:future perspectives of mitochondrial pharmaceutics in cardiovascular diseases[J]. World J Cardiol,2014,6(10):1091-1099.
[6] 刘杰. 阿霉素长循环脂质体的研制[D]. 河北医科大学,2007.
[7] Swain SM,Whaley FS,Ewer MS. Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J]. Cancer,2003,97(11):2869-2879.
[8] Vejpongsa P,Yeh ET. Prevention of anthracycline-induced cardiotoxicity:challenges and opportunities[J]. J Am Coll Cardiol,2014,64(9):938-945.
[9] Legha SS,Benjamin RS,Mackay B,et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer[J]. Cancer,1982,49(9):1762-1766.
[10] Lipshultz SE,Miller TL,Lipsitz SR,et al. Continuous versus bolus infusion of doxorubicin in children with all:long-term cardiac outcomes[J]. Pediatrics,2012,130(6):1003-1011.
[11] Piroth MD,Baumann R,Budach W,et al. Heart toxicity from breast cancer radiotherapy:current findings,assessment,and prevention[J]. Strahlenther Onkol,2019,195(1):1-12.
[12] Kaidar-Person O,Zagar TM,Oldan JD,et al. Early cardiac perfusion defects after left-sided radiation therapy for breast cancer:is there a volume response?[J]. Breast Cancer Res Treat,2017,164(2):253-262.
[13] Rochet N,Drake JI,Harrington K,et al. Deep inspiration breath-hold technique in left-sided breast cancer radiation therapy:evaluating cardiac contact distance as a predictor of cardiac exposure for patient selection[J]. Pract Radiat Oncol,2015,5(3):e127-e134.
[14] Innominato PF,Giacchetti S,Moreau T,et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)[J]. Chronobiol Int,2011,28(7):586-600.
[15] Sewlall S,Pillay V,Danckwerts MP,et al. A timely review of state-of-the-art chronopharmaceuticals synchronized with biological rhythms[J]. Curr Drug Deliv,2010,7(5):370-388.
[16] Altinok A,Lévi F,Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling[J]. Eur J Pharm Sci,2009,36(1):20-38.
[17] Gupta D,Shukla P,Munshi A,et al. Cardioprotective radiotherapy:the circadian way[J]. Med Hypotheses,2012,78(3):353-355.
[18] 易培强,陈佳艺. 放射联合靶向药物治疗乳腺癌的心脏安全性探讨[J]. 药学进展,2018,42(7):506-511.
[19] 王雪清,李文新. 蒽环类药物的心脏毒性研究进展[J]. 世界最新医学信息文摘,2019,19(35):75-76.
[20] Patel AA,Labovitz AJ. Advanced echocardiographic techniques in detection of cardiotoxicity[J]. Curr Treat Options Cardiovasc Med,2016,18(4):28.
[21] Skála M,Hanousková B,Skálová L,et al. MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity[J]. Arch Toxicol,2019,93(1):1-9.
[22] Tromp J,Steggink LC,van Veldhuisen DJ,et al. Cardio-oncology:progress in diagnosis and treatment of cardiac dysfunction[J]. Clin Pharmacol Ther,2017,101(4):481-490.
[23] Hameau R,Gabrielli L,Garrido M,et al. Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units[J]. Rev Med Chil,2018,146(1):68-77.
[24] 冯泽豪,姜萌,卜军. 心脏磁共振评价化疗所致心肌损伤的研究进展[J]. 心血管病学进展,2019,40(5):667-672.
[25] Lyu YL,Kerrigan JE,Lin CP,et al. Topoisomerase Ⅱbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane[J]. Cancer Res,2007,67(18):8839-8846.
[26] 马军,秦叔逵,沈志祥. 蒽环类药物心脏毒性防治指南(2013年版)[J]. 临床肿瘤学杂志,2013,18(10):925-934.
[27] van Dalen EC,Caron HN,Dickinson HO,et al. Cardioprotective interventions for cancer patients receiving anthracyclines[J]. Cochrane Database Syst Rev,2011,(6):CD003917.
[28] Howlader N,Ries LA,Mariotto AB,et al. Improved estimates of cancer-specific survival rates from population-based data[J]. J Natl Cancer Inst,2010,102(20):1584-1598.
[29] Reichardt P,Tabone MD,Mora J,et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity:re-evaluating the European labeling[J]. Future Oncol,2018,14(25):2663-2676.
[30] Tahover E,Segal A,Isacson R,et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer:a retrospective cohort study with a comparative analysis of toxicity and survival[J]. Anticancer Drugs,2017,28(7):787-794.
[31] 陈莉莉,张晗,姜小庆,等. 中药有效成分拮抗化疗药物心脏毒性的分子机制研究进展[J]. 辽宁中医杂志,2013,40(11):2387-2391.
[32] Yun S,Vincelette ND,Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients:a systematic review and meta-analysis[J]. Postgrad Med J,2015,91(1081):627-633.
[33] Cardinale D,Colombo A,Sandri MT,et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition[J]. Circulation,2006,114(23):2474-2481.
[34] Cardinale D,Colombo A,Lamantia G,et al. Anthracycline-induced cardiomyopathy:clinical relevance and response to pharmacologic therapy[J]. J Am Coll Cardiol,2010,55(3):213-220.
[35] Riad A,Bien S,Westermann D,et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice[J]. Cancer Res,2009,69(2):695-699.
[36] Acar Z,Kale A,Turgut M,et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy[J]. J Am Coll Cardiol,2011,58(9):988-989.
[37] Chotenimitkhun R,D’Agostino RJ,Lawrence JA,et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function[J]. Can J Cardiol,2015,31(3):302-307.
[38] Wu SZ,Tao LY,Wang JN,et al. Amifostine pretreatment attenuates myocardial ischemia/reperfusion injury by inhibiting apoptosis and oxidative stress[J]. Oxid Med Cell Longev,2017,2017:4130824.
[39] Jones LW,Habel LA,Weltzien E,et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer[J]. J Clin Oncol,2016,34(23):2743-2749.
[40] Wang J,Wu Y,Yuan F,et al. Chronic intermittent hypobaric hypoxia attenuates radiation induced heart damage in rats[J]. Life Sci,2016,160:57-63.
[41] Lee Y,Naruse Y,Tanaka K. Effectiveness and long-term outcomes of surgical intervention for constrictive epicardium in constrictive pericarditis[J]. Gen Thorac Cardiovasc Surg,2018,66(3):137-144.
相似文献/References:
[1]唐雨琦 关旭敏 方凤奇 刘基巍 夏云龙.吉西他滨引起心脏毒性的研究现状[J].心血管病学进展,2020,(9):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
TANG Yuqi,GUAN Xumin,FANG Fengqi,et al.Cardiotoxicity Induced by Gemcitabine[J].Advances in Cardiovascular Diseases,2020,(7):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
[2]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(7):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[3]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(7):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
[4]杨懿 牟云飞 任福强 黄鑫 王园.表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析[J].心血管病学进展,2022,(8):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
YANG Yi,MU Yunfei,REN Fuqiang,et al.A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(7):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
[5]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(7):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[6]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(7):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[7]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(7):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[8]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(7):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[9]赵 珂 陈晓姝 魏希进 张 娟 刘 杨 卞雨敬 袁 杰.铁死亡的调控机制及其在蒽环类药物心脏毒性中的研究进展[J].心血管病学进展,2024,(3):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 0000,et al.Regulatory Mechanism of Ferroptosis and Its Progress in Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(7):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]